Virtual Clinical Trials Find Bigger Voice As COVID-19 Forces Pharma Rethink
Enforced Postponement Of Some Clinical Trials Has Compelled Therapy Developers To Seek Alternatives Routes
The use of virtual, real-time and at-home testing to provide clinical trials data has been steadily gaining the interest of the health care industry. COVID-19 has put this opportunity into sharper focus, says CNS trials technology developer Cambridge Cognition, which is now adding a voice option to its portfolio.
You may also be interested in...
In this Device Week, Ashley Yeo asks PB Consulting managing director Dan Jones about the adjustments needed by UK medtechs as they face a confluence of change brought about by Brexit, COVID-19 and NHS reform, at a time when the MHRA is also coming under increased scrutiny.
Entrepreneur Carlo Rivis, one of In Vivo’s Rising Leaders, brought his disruptive innovation approaches to in-silico trials and digital avatar developer Computational Life, and now he is doing the same at Innovation Discovery.
COVID-19 is of no lesser importance to the UK medtech industry, but attention is now refocusing on Brexit, future regulation and trade deals.